

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/087,200	03/01/2002	James E. Fleming	390054,401C1	1354	
500	7590 12/16/2003		EXAM	EXAMINER	
SEED INT	ELLECTUAL PROPI	LEARY, LOUISE N			
SUITE 6300		ART UNIT	PAPER NUMBER		
SEATTLE,	WA 98104-7092	1654			
			DATE MAILED: 12/16/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicat	ion No	Applicant(s)				
	Office Action Summary	10/087,2		FLEMING ET AL.				
		Examine		Art Unit				
	The MAILING DATE of this communication	Louise N		1654				
Period fo	or Reply	appears on tr	e cover sneet with the co	orrespondence address	,			
THE Exte after - If the - If NC - Failu - Any i	ORTENED STATUTORY PERIOD FOR REMAILING DATE OF THIS COMMUNICATIOnsions of time may be available under the provisions of 37 CF SIX (6) MONTHS from the mailing date of this communication period for reply specified above is less than thirty (30) days, at period for reply is specified above, the maximum statutory pere to reply within the set or extended period for reply will, by steply received by the Office later than three months after the maximum adjustment. See 37 CFR 1.704(b).	DN. R 1.136(a). In no e n. a reply within the sta eriod will apply and v tatute, cause the ap	vent, however, may a reply be time tutory minimum of thirty (30) days vill expire SIX (6) MONTHS from to	ely filed will be considered timely. he mailing date of this communication (35 U.S.C. & 133)	ion.			
1)[Responsive to communication(s) filed on							
2a) <u></u> □		This action is	non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
· _	on of Claims							
	Claim(s) <u>1-23</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
	Claim(s) is/are allowed.							
	Claim(s) <u>1-10 and 15-23</u> is/are rejected.							
	Claim(s) 11-14 is/are objected to.							
	Claim(s) are subject to restriction an on Papers	d/or election r	equirement.					
9) 🗌 -	The specification is objected to by the Exam	iner.						
10)⊠ 7	he drawing(s) filed on <u>01 March 2002</u> is/are	e: a)⊠ accepte	ed or b) objected to by t	he Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12)☐ The oath or declaration is objected to by the Examiner.								
Priority u	nder 35 U.S.C. §§ 119 and 120							
13)	Acknowledgment is made of a claim for fore	eign priority ur	der 35 U.S.C. § 119(a)-	(d) or (f).				
a)[☐ All b)☐ Some * c)☐ None of:							
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
	 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
		estic priority u	nder 35 U.S.C. §§ 120 a	nd/or 121.				
Attachment(
2) 🔲 Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s	s) <u>2</u> .		PTO-413) Paper No(s) tent Application (PTO-152)				

Art Unit: 1654

1. Claims 1-23 are pending in this application.

2. Claims 21-23 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 21-23 are rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential elements, such omission amounting to a gap between the elements. See MPEP § 2172.01. The omitted elements are: instructions for detecting or quantifying viable cells in the kits claimed.

Correction is required to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 15-23 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 21-24 of

Art Unit: 1654

copending Application No. 09/696710. Although the conflicting claims are not identical, they are not patentably distinct from each other because the kits described in this invention comprise identical starting materials that are used for the same purpose of "quantifying viable cells" as claimed in the invention of U.S. copending Application No. 09/696710. In addition, with respect to the phrase "[A kit for detecting or quantifying viable cells]", it is noted that viable cells are detected before being quantified. Hence, there is substantial overlap of the subject matter claimed in both inventions.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-10 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Ligler et al (US 5,496,700).

Ligler et al disclose a method for detecting viable cells in a sample comprising the steps of contacting the sample with a fluorescent dye that binds to target

Art Unit: 1654

components in the cells. Ligler et al disclose a fluorescent method for detection of microorganisms including bacteria, viruses, rickettsia and fungi. See the abstract. Ligler et al disclose a fluorescent method for detection of vegetative *Bacillus anthracis*. Also, Ligler et al disclose the use of various nucleic acid dyes, e.g. acridine orange. See columns 8-14. Thus, Ligler et al disclose the invention claimed except for addressing detecting yeast.

However, regarding detecting yeast using the method claimed, it is noted that Ligler et al detect "microorganisms" which encompasses yeast. Ligler et al disclose all the limitations claimed except the inherent property that yeast are microorganisms which anticipates or renders obvious the invention claimed.

The burden of proof is on applicants to show patentably distinct differences between the Ligler et al disclosure and the invention as claimed herein.

- 5. Claims 11-14 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Louise N. Leary whose telephone number is (703) 308-3533. The examiner can normally be reached on Monday to Friday from 10 to 6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback, can be reached on (703) 306-3220. The fax phone

Art Unit: 1654

Page 5

number for the organization where this application or proceeding is assigned is (703) 872-9306

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

For 24 hour access to patent application information, 7 days a week, or for filing patent applications electronically, please visit our website at www.uspto.gov and click on the button "Patent Electronic Business Center" for more information.

PRIMARY EXAMINER

December 10, 2003